Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs ZYP Medical

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and ZYP Medical head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 82 · Grade C

ZYP Medical

Visit ZYP Medical Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 75 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make ZYP Medical a bad call — it's best for readers who want men in ne, ia, sd, ks, co, or az wanting low-cost compounded glp-1s with oral option. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
78
Supply Reliability
95
69
Transparency
90
88
Access Breadth
93
62
Clinical Oversight
92
80
Track Record
88
72
CoreAge RxBrief Score 94 · 75ZYP Medical

Price, coverage & the tracker

CoreAge RxZYP Medical
Brief Score94/100 (A)75/100 (C)
Semaglutide$149/mo$150/mo
Tirzepatide$349/mo$233/mo
CoverageAll 50 states6 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

ZYP Medical: New to the tracker on 1 August 2026. The published line reads $150/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.